Literature DB >> 3257742

Specificity of antibodies secreted by hybridomas generated from activated B cells in the mesenteric lymph nodes of patients with inflammatory bowel disease.

L P Chao1, J Steele, C Rodrigues, J Lennard-Jones, J L Stanford, C Spiliadis, G A Rook.   

Abstract

Hybridomas have been prepared from active B cells in lymphoid tissue draining lesions of Crohn's disease (CD) and ulcerative colitis (UC), by fusion of fresh mesenteric lymph node suspensions with the murine JK myeloma. Two hundred and fifty nine immunoglobulin secreting hybridomas have been obtained from nine patients. The antibodies have been screened for binding to food antigens, sections of human gut, and bacteria including two unidentified acid fast isolates from CD lymph nodes. Autoantibodies, and antibodies to food antigens implicated by others in the aetiology of CD were rare, comprising 1.2%, and 2.5% respectively. Most donors yielded none of these. Thus neither food antigens nor autoantigens are major antigenic stimuli in nodes draining inflammatory bowel disease. On the other hand between 19% and 83% of supernatants from different donors bound to one or more bacterial genus. The mycobacteria and the CD isolates were amongst the genera to which most antibodies bound, though binding to E coli was more frequent. Significantly more CD than UC derived supernatants bound to BCG. As mycobacteria are not though to be part of the normal bowel flora, the high percentage of hybridomas secreting antibodies which bind to this genus is surprising.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257742      PMCID: PMC1433249          DOI: 10.1136/gut.29.1.35

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  A CONTROLLED THERAPEUTIC TRIAL OF VARIOUS DIETS IN ULCERATIVE COLITIS.

Authors:  R WRIGHT; S C TRUELOVE
Journal:  Br Med J       Date:  1965-07-17

2.  Escherichia coli antibodies in patients with inflammatory bowel disease.

Authors:  S Tabaqchali; D P O'Donoghue; K A Bettelheim
Journal:  Gut       Date:  1978-02       Impact factor: 23.059

3.  Enterobacterial common antigen-induced lymphocyte reactivity in inflammatory bowel disease.

Authors:  D M Bull; T F Ignaczak
Journal:  Gastroenterology       Date:  1973-01       Impact factor: 22.682

4.  Cytotoxicity of mononuclear cells for autologous colonic epithelial cells in colonic diseases.

Authors:  R G Shorter; D B McGill; R C Bahn
Journal:  Gastroenterology       Date:  1984-01       Impact factor: 22.682

5.  Anti-colon antibody and lymphocytophilic antibody in ulcerative colitis.

Authors:  T Hibi; S Aiso; T Yoshida; M Watanabe; H Asakura; S Tsuru; M Tsuchiya
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

6.  Mycobacteria as a possible cause of inflammatory bowel disease.

Authors:  W R Burnham; J E Lennard-Jones; J L Stanford; R G Bird
Journal:  Lancet       Date:  1978-09-30       Impact factor: 79.321

7.  Antibodies detectable by counterimmunoelectrophoresis against Bacteroides antigens in serum of patients with inflammatory bowel disease.

Authors:  C J Helphingstine; D J Hentges; B J Campbell; J Butt; J T Barrett
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

8.  T-cell-dependent polyclonal activation by soluble mycobacterial extracts of B cells in peripheral blood mononuclear cell populations from leprosy patients and normal donors.

Authors:  B Fleming; G A Rook
Journal:  Immunology       Date:  1982-12       Impact factor: 7.397

9.  Agglutinins to bacteria in Crohn's disease.

Authors:  N Matthews; J F Mayberry; J Rhodes; L Neale; J Munro; F Wensinck; G H Lawson; A C Rowland; G A Berkhoff; S W Barthold
Journal:  Gut       Date:  1980-05       Impact factor: 23.059

10.  Detection of colonic antigen(s) in tissues from ulcerative colitis using purified colitis colon tissue-bound IgG (CCA-IgG).

Authors:  T Nagai; K M Das
Journal:  Gastroenterology       Date:  1981-09       Impact factor: 22.682

View more
  10 in total

1.  Period and generation effects on mortality from idiopathic inflammatory bowel disease.

Authors:  A Sonnenberg; T R Koch
Journal:  Dig Dis Sci       Date:  1989-11       Impact factor: 3.199

2.  Oral administration of unmodified colonic but not small intestinal antigens protects rats from hapten-induced colitis.

Authors:  A Dasgupta; K V Kesari; K K Ramaswamy; P S Amenta; K M Das
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

3.  Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria.

Authors:  A Macpherson; U Y Khoo; I Forgacs; J Philpott-Howard; I Bjarnason
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

4.  Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon.

Authors:  T S Halstensen; T E Mollnes; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

Review 5.  Inflammatory mediators in chronic inflammatory bowel diseases.

Authors:  V Gross; T Andus; H G Leser; M Roth; J Schölmerich
Journal:  Klin Wochenschr       Date:  1991-12-15

Review 6.  B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.

Authors:  Mathieu Uzzan; Jean-Frederic Colombel; Andrea Cerutti; Xavier Treton; Saurabh Mehandru
Journal:  Dig Dis Sci       Date:  2016-09-21       Impact factor: 3.199

7.  Monoclonal immunoglobulin A derived from peritoneal B cells is encoded by both germ line and somatically mutated VH genes and is reactive with commensal bacteria.

Authors:  N A Bos; J C Bun; S H Popma; E R Cebra; G J Deenen; M J van der Cammen; F G Kroese; J J Cebra
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

8.  Induction of suppressor cells by Mycobacterium paratuberculosis antigen in inflammatory bowel disease.

Authors:  E C Ebert; B D Bhatt; S Liu; K M Das
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

9.  Intestinal expression and cellular immune responses to human heat-shock protein 60 in Crohn's disease.

Authors:  M E Baca-Estrada; R S Gupta; R H Stead; K Croitoru
Journal:  Dig Dis Sci       Date:  1994-03       Impact factor: 3.199

Review 10.  Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease.

Authors:  Marko Kumric; Piero Marin Zivkovic; Tina Ticinovic Kurir; Josip Vrdoljak; Marino Vilovic; Dinko Martinovic; Andre Bratanic; Ivan Kresimir Lizatovic; Josko Bozic
Journal:  Diagnostics (Basel)       Date:  2021-12-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.